PrintWelcome to MitraClip.com
On November 2, 2009, Abbott announced the acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves. Evalve was incorporated in 1999 to design, develop, manufacture and market innovative devices to enable percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and cost associated with current open, arrested heart surgical options. The company's present development and clinical efforts are focused on mitral valve repair with the MitraClip system.
MitraClip is a trademark of the Abbott Group of Companies. Evalve obtained CE mark approval in 2008 for the MitraClip system, the world's first percutaneous valve repair system. Information contained herein for distribution outside the U.S. and Japan only. Please check the regulatory status of the device before distribution in areas where CE marking is not the regulation in force.
Click on a region below for more information.
- Region where the MitraClip therapy is currently available
- Currently selected region, click for more information
- Region where the MitraClip therapy is not currently available
